PL2004657T3 - Skondensowane pochodne imidazolowe jako inhibitory syntazy aldosteronu - Google Patents

Skondensowane pochodne imidazolowe jako inhibitory syntazy aldosteronu

Info

Publication number
PL2004657T3
PL2004657T3 PL07728050T PL07728050T PL2004657T3 PL 2004657 T3 PL2004657 T3 PL 2004657T3 PL 07728050 T PL07728050 T PL 07728050T PL 07728050 T PL07728050 T PL 07728050T PL 2004657 T3 PL2004657 T3 PL 2004657T3
Authority
PL
Poland
Prior art keywords
imidazole derivatives
synthase inhibitors
aldosterone synthase
condensed imidazole
condensed
Prior art date
Application number
PL07728050T
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Aleksandar Stojanovic
Christiane Marti
Stefan Stutz
Bibia Bennacer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2004657T3 publication Critical patent/PL2004657T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL07728050T 2006-04-12 2007-04-12 Skondensowane pochodne imidazolowe jako inhibitory syntazy aldosteronu PL2004657T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH6172006 2006-04-12
PCT/EP2007/053583 WO2007116097A1 (en) 2006-04-12 2007-04-12 Condensed imidazole derivatives as aldosterone synthase inhibitors
EP07728050A EP2004657B1 (en) 2006-04-12 2007-04-12 Condensed imidazole derivatives as aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
PL2004657T3 true PL2004657T3 (pl) 2011-02-28

Family

ID=38171569

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07728050T PL2004657T3 (pl) 2006-04-12 2007-04-12 Skondensowane pochodne imidazolowe jako inhibitory syntazy aldosteronu

Country Status (14)

Country Link
US (3) US7799780B2 (pl)
EP (2) EP2004657B1 (pl)
JP (2) JP4980417B2 (pl)
CN (2) CN101421278A (pl)
AR (1) AR060591A1 (pl)
AT (2) ATE479692T1 (pl)
BR (2) BRPI0709948A2 (pl)
CA (2) CA2649214A1 (pl)
DE (2) DE602007008860D1 (pl)
ES (1) ES2352092T3 (pl)
IL (2) IL193065A0 (pl)
PL (1) PL2004657T3 (pl)
TW (1) TW200808812A (pl)
WO (2) WO2007116097A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5179174B2 (ja) * 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体
EP2277939B1 (en) 2005-03-24 2017-02-22 Bridgestone Corporation Compounding silica-reinforced rubber with low volatile organic compound (VOC) emission
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
AU2007249695A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US8962746B2 (en) 2007-12-27 2015-02-24 Bridgestone Corporation Methods of making blocked-mercapto alkoxy-modified silsesquioxane compounds
US8794282B2 (en) 2007-12-31 2014-08-05 Bridgestone Corporation Amino alkoxy-modified silsesquioxane adhesives for improved metal adhesion and metal adhesion retention to cured rubber
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
SG176009A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
WO2013120771A1 (en) * 2012-02-13 2013-08-22 F. Hoffmann-La Roche Ag Imidazolylketone derivatives asd aldosterone synthase inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
US11401440B2 (en) 2014-12-31 2022-08-02 Bridgestone Corporation Amino alkoxy-modified silsesquioxane adhesives for adhering steel alloy to rubber
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
JP2022507958A (ja) 2018-11-27 2022-01-18 ノバルティス アーゲー 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
PY1998404A (es) 2018-11-27 2021-06-17 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS579787A (en) 1980-06-20 1982-01-19 Ss Pharmaceut Co Ltd Thiazinobenzimidazole derivative and its preparation
JPH0670064B2 (ja) * 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
WO1997000257A1 (en) * 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
HUP0301335A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DK1537114T3 (da) * 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
US7612088B2 (en) * 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
CA2568164A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
JP5179174B2 (ja) * 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds

Also Published As

Publication number Publication date
JP2009532442A (ja) 2009-09-10
CA2649214A1 (en) 2007-10-18
ATE484510T1 (de) 2010-10-15
BRPI0710596A2 (pt) 2011-08-16
WO2007116097A1 (en) 2007-10-18
CA2641473C (en) 2011-11-01
US20090012068A1 (en) 2009-01-08
WO2007116100A1 (en) 2007-10-18
ES2352092T3 (es) 2011-02-15
IL193065A0 (en) 2009-02-11
JP2010523465A (ja) 2010-07-15
CN101415716B (zh) 2012-12-12
AR060591A1 (es) 2008-07-02
ATE479692T1 (de) 2010-09-15
BRPI0709948A2 (pt) 2011-08-02
CN101415716A (zh) 2009-04-22
CN101421278A (zh) 2009-04-29
EP2004658A1 (en) 2008-12-24
DE602007009812D1 (de) 2010-11-25
US20090048241A1 (en) 2009-02-19
EP2004657B1 (en) 2010-09-01
US7799780B2 (en) 2010-09-21
TW200808812A (en) 2008-02-16
US7795253B2 (en) 2010-09-14
IL194582A0 (en) 2009-08-03
EP2004658B1 (en) 2010-10-13
US20100305110A1 (en) 2010-12-02
US8076327B2 (en) 2011-12-13
DE602007008860D1 (de) 2010-10-14
CA2641473A1 (en) 2007-10-18
EP2004657A1 (en) 2008-12-24
JP4980417B2 (ja) 2012-07-18

Similar Documents

Publication Publication Date Title
IL193065A0 (en) Condensed imidazole derivatives as aldosterone synthase inhibitors
IL257083B (en) The history of phosphorus as kinase inhibitors
IL200906A0 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
IL209834A (en) Phenylimidazole derivatives as a10pde enzyme sequences
ZA200904138B (en) Substituted spirochromanone derivatives as acc inhibitors
IL211693A0 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL187646A0 (en) Fused imidazole derivatives and use thereof as aldosterone synthase inhibitors
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
AP2010005521A0 (en) Macrocyclic indole derivatives useful as hepatitisvirus inhibitors.
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA200902640B (en) Purines as PKC-Theta inhibitors
GB0811091D0 (en) CYP26 Inhibitors
PT1937673E (pt) Derivados de imidazol como derivados do tafi-a
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1122802A (en) Condensed imidazole derivatives as aldosterone synthase inhibitors
HK1122805A (en) Condensed imidazole derivatives as aromatase inhibitors